Proteostasis

Proteostasis Therapeutics Announces Global License Agreement with Genentech

Retrieved on: 
Monday, December 17, 2018
Biotechnology, Biology, Nature, Protein folding, Homeostasis, Proteomics, Proteostasis, Specialty drugs, Genentech, Biopharmaceutical

Under the terms of the agreement, in exchange for rights to these small molecule modulators, Proteostasis is eligible to receive upfront and milestone payments of over $100 million.

Key Points: 
  • Under the terms of the agreement, in exchange for rights to these small molecule modulators, Proteostasis is eligible to receive upfront and milestone payments of over $100 million.
  • In addition, Proteostasis is eligible to receive tiered royalties on sales of medicines resulting from the license agreement.
  • "We are thrilled to enter into this agreement with Genentech, an industry leader with a proven record of success in small molecule research and development," said Meenu Chhabra, President and CEO of Proteostasis Therapeutics.
  • Proteostasis Therapeutics, Inc.is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing.

Proteostasis Therapeutics Announces Positive Preliminary Results from Proprietary Doublet in Cystic Fibrosis Patients

Retrieved on: 
Wednesday, October 17, 2018
Biology, Channelopathies, Cystic fibrosis, RTT, Proteostasis, Pakistan Tehreek-e-Insaf, Gastroenterology, Genetic genealogy

PK results were as expected and confirmed a once-a-day dosing profile for both PTI-801 and PTI-808.

Key Points: 
  • PK results were as expected and confirmed a once-a-day dosing profile for both PTI-801 and PTI-808.
  • "Doublet combinations, the current standard of care for many CF patients, are the benchmark for current treatment in cystic fibrosis.
  • These results begin to confirm the exciting clinical effect of PTI's drug pipelinewith more clinical data from both higher doses and proprietary triplet combinations to come."
  • Proteostasis Therapeutics, Inc.is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing.

Proteostasis Therapeutics to Present at the Cantor Global Healthcare Conference

Retrieved on: 
Thursday, September 27, 2018
Biology, Biotechnology, Nature, Protein folding, Homeostasis, Proteomics, Proteostasis, Biopharmaceutical, Cystic fibrosis, Forward-looking statement

A live audio webcast of theCantor Global Healthcare Conference presentation will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com .

Key Points: 
  • A live audio webcast of theCantor Global Healthcare Conference presentation will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com .
  • A replay of the webcast will be available on the Company's website following the presentation.
  • Proteostasis Therapeutics, Inc.is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing.
  • We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Proteostasis Announces Presentations at the 41st European Cystic Fibrosis Society Conference

Retrieved on: 
Friday, June 1, 2018
Cystic fibrosis, Biology, ABC transporters, Chemistry, Cystic fibrosis transmembrane conductance regulator, Tezacaftor, Proteostasis, Chloride channel opener

Following the presentations at ECFS, the presentations will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com .

Key Points: 
  • Following the presentations at ECFS, the presentations will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com .
  • PTI-428 is designed to increase the amount of newly synthesized cystic fibrosis transmembrane conductance regulator(CFTR) protein and to act synergistically with other CFTR modulators, such as correctors and potentiators.
  • In April, the TDN also endorsed Proteostasis' study protocol to investigate PTI-428 in CF patients on background Symdeko therapy.
  • Proteostasis Therapeutics, Inc.is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing.

Proteostasis Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

Retrieved on: 
Thursday, May 31, 2018
Biology, Biotechnology, Protein folding, Nature, Homeostasis, Proteomics, Proteostasis, Cystic fibrosis, Biopharmaceutical

BOSTON, May 31, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Po-Shun Lee, M.D., the Company's Chief Medical Officer, will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 2:30 p.m.

Key Points: 
  • BOSTON, May 31, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Po-Shun Lee, M.D., the Company's Chief Medical Officer, will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 2:30 p.m.
  • A live audio webcast of theJefferies 2018 Global Healthcare Conference presentation will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com .
  • Proteostasis Therapeutics, Inc.is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing.
  • We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.